Nuvation Bio (NUVB) Stock Price, News & Analysis

Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Key Stats

• Today's Range: $2.57 to $2.82
• 50-Day Range: $2.19 to $3.01
• 52-Week Range: $1.43 to $4.16
• Volume: 2.26 million shs
• Average Volume: 1.61 million shs
• Market Capitalization: $898.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.60
• Consensus Rating: Buy

Nuvation Bio Stock Analysis - MarketRank™

Nuvation Bio scored higher than 48% of companies evaluated by MarketBeat, and ranked 584th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nuvation Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nuvation Bio are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvation Bio is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvation Bio is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvation Bio has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.17% of the float of Nuvation Bio has been sold short.

Short Interest Ratio / Days to Cover

Nuvation Bio has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Nuvation Bio has recently increased by 28.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvation Bio does not currently pay a dividend.

Dividend Growth

Nuvation Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.17% of the float of Nuvation Bio has been sold short.

Short Interest Ratio / Days to Cover

Nuvation Bio has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Nuvation Bio has recently increased by 28.26%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.44

News Sentiment

Nuvation Bio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Nuvation Bio this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 3 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Nuvation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $220,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.07% of the stock of Nuvation Bio is held by insiders.

Percentage Held by Institutions

61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NUVB Stock Analysis - Frequently Asked Questions

How have NUVB shares performed this year?

Nuvation Bio's stock was trading at $1.51 at the beginning of the year. Since then, NUVB shares have increased by 76.8% and is now trading at $2.67.
View the best growth stocks for 2024 here.

How were Nuvation Bio's earnings last quarter?

Nuvation Bio Inc. (NYSE:NUVB) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02. The company earned $0.73 million during the quarter.

Who are Nuvation Bio's major shareholders?

Top institutional investors of Nuvation Bio include FMR LLC (11.73%), State Street Corp (1.67%), Geode Capital Management LLC (1.62%) and Charles Schwab Investment Management Inc. (0.56%). Insiders that own company stock include Fund V LP Omega, Oleg Nodelman, Xiangmin Cui and Robert Mashal.
View institutional ownership trends.

How do I buy shares of Nuvation Bio?

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Nuvation Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 12/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NUVB
• CUSIP: N/A
• CIK: 1811063
• Web: www.nuvationbio.com
• Phone: 332-208-6102
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.60
• High Stock Price Target: $10.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +147.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-75,800,000.00
• Net Margins: N/A
• Pretax Margin: -24,619.84%
• Return on Equity: -21.89%
• Return on Assets: -17.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.57
• Quick Ratio: 9.57

Sales & Book Value

• Annual Sales: $2.16 million
• Price / Sales: 415.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.76 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 336,567,000
• Free Float: 319,503,000
• Market Cap: $898.63 million
• Optionable: Optionable
• Beta: 1.46